These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 8607823

  • 1. Inhibition of vesicular stomatitis virus replication by epidermal growth factor in human epidermoid A-431 cells.
    Korutla L, Kumar R.
    Biochem Biophys Res Commun; 1996 Mar 27; 220(3):670-4. PubMed ID: 8607823
    [Abstract] [Full Text] [Related]

  • 2. Mechanism of interferon action. Interferon alpha inhibits vesicular stomatitis virus primary transcript accumulation in P1/eIF-2 alpha protein kinase-deficient human fibroblast cells.
    Zhang XT, Samuel CE.
    J Biol Regul Homeost Agents; 1987 Mar 27; 1(4):157-65. PubMed ID: 2845723
    [Abstract] [Full Text] [Related]

  • 3. VSV replication in neurons is inhibited by type I IFN at multiple stages of infection.
    Trottier MD, Palian BM, Reiss CS.
    Virology; 2005 Mar 15; 333(2):215-25. PubMed ID: 15721356
    [Abstract] [Full Text] [Related]

  • 4. Antiviral effect of a synthetic brassinosteroid on the replication of vesicular stomatitis virus in Vero cells.
    Romanutti C, Castilla V, Coto CE, Wachsman MB.
    Int J Antimicrob Agents; 2007 Mar 15; 29(3):311-6. PubMed ID: 17275263
    [Abstract] [Full Text] [Related]

  • 5. Vaccinia virus and the EGF receptor: a portal for infectivity?
    Marsh YV, Eppstein DA.
    J Cell Biochem; 1987 Aug 15; 34(4):239-45. PubMed ID: 3497935
    [Abstract] [Full Text] [Related]

  • 6. Effect of exogenous tumor necrosis factor alpha, interleukin 6 and interferons on vesicular stomatitis virus replication in human placenta and amniotic membrane organ cultures.
    Paradowska E, Blach-Olszewska Z, Gierlińska M, Woytoń J.
    Arch Immunol Ther Exp (Warsz); 1996 Aug 15; 44(1):57-62. PubMed ID: 8874771
    [Abstract] [Full Text] [Related]

  • 7. Antiviral effects of recombinant human tumor necrosis factor.
    Ito M, O'Malley JA.
    Lymphokine Res; 1987 Aug 15; 6(4):309-18. PubMed ID: 2448553
    [Abstract] [Full Text] [Related]

  • 8. In vitro inhibition of vesicular stomatitis virus replication by purified porcine Mx1 protein fused to HIV-1 Tat protein transduction domain (PTD).
    Zhang XM, He DN, Zhou B, Pang R, Liu K, Zhao J, Chen PY.
    Antiviral Res; 2013 Aug 15; 99(2):149-57. PubMed ID: 23727591
    [Abstract] [Full Text] [Related]

  • 9. Effect of combined alpha IFN and prostaglandin A1 treatment on vesicular stomatitis virus replication and heat shock protein synthesis in epithelial cells.
    Pica F, Rossi A, Santirocco N, Palamara A, Garaci E, Santoro MG.
    Antiviral Res; 1996 Mar 15; 29(2-3):187-98. PubMed ID: 8739598
    [Abstract] [Full Text] [Related]

  • 10. Mechanisms of cytokine-mediated inhibition of viral replication.
    Komatsu T, Srivastava N, Revzin M, Ireland DD, Chesler D, Reiss CS.
    Virology; 1999 Jul 05; 259(2):334-41. PubMed ID: 10388658
    [Abstract] [Full Text] [Related]

  • 11. The effect of cicloxolone sodium on the replication of vesicular stomatitis virus in BSC-1 cells.
    Dargan DJ, Galt CB, Subak-Sharpe JH.
    J Gen Virol; 1992 Feb 05; 73 ( Pt 2)():397-406. PubMed ID: 1311361
    [Abstract] [Full Text] [Related]

  • 12. Attenuation of recombinant vesicular stomatitis viruses encoding mutant glycoproteins demonstrate a critical role for maintaining a high pH threshold for membrane fusion in viral fitness.
    Fredericksen BL, Whitt MA.
    Virology; 1998 Jan 20; 240(2):349-58. PubMed ID: 9454708
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of VSV and EMCV replication by the interferon-induced GTPase, mGBP-2: differential requirement for wild-type GTP binding domain.
    Carter CC, Gorbacheva VY, Vestal DJ.
    Arch Virol; 2005 Jun 20; 150(6):1213-20. PubMed ID: 15717119
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of vesicular stomatitis virus multiplication in Vero cells by 2-deoxy-D-glucose.
    Sabina LR, Telasco CE.
    Acta Virol; 1979 May 20; 23(3):210-20. PubMed ID: 41433
    [Abstract] [Full Text] [Related]

  • 15. Mode of selection and experimental evolution of antiviral drugs resistance in vesicular stomatitis virus.
    Cuevas JM, Sanjuán R, Moya A, Elena SF.
    Infect Genet Evol; 2005 Jan 20; 5(1):55-65. PubMed ID: 15567139
    [Abstract] [Full Text] [Related]

  • 16. Functional significance of globotriaosyl ceramide in interferon-alpha(2)/type 1 interferon receptor-mediated antiviral activity.
    Khine AA, Lingwood CA.
    J Cell Physiol; 2000 Jan 20; 182(1):97-108. PubMed ID: 10567921
    [Abstract] [Full Text] [Related]

  • 17. [How to make an ally of an "inactive" product: the example of interferon].
    Lavelle F.
    Bull Cancer; 2000 Sep 20; 87(9):621-2. PubMed ID: 11184449
    [No Abstract] [Full Text] [Related]

  • 18. Progression of a vesicular stomatitis virus infection in primary lymphocytes is restricted at multiple levels during B cell activation.
    Schmidt MR, Gravel KA, Woodland RT.
    J Immunol; 1995 Sep 01; 155(5):2533-44. PubMed ID: 7650383
    [Abstract] [Full Text] [Related]

  • 19. Interferon-induced guanylate binding protein-1 (GBP-1) mediates an antiviral effect against vesicular stomatitis virus and encephalomyocarditis virus.
    Anderson SL, Carton JM, Lou J, Xing L, Rubin BY.
    Virology; 1999 Mar 30; 256(1):8-14. PubMed ID: 10087221
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.